90.4% overall protective power recombinant protein new crown vaccine candidate phase 3 clinical results...

On June 14, 2021, Novavax announced that its recombinant protein-based nanoparticle new crown vaccine candidate NVX-CoV2373 has reached the primary endpoint in a pivotal phase 3 clinical trial, with an overall protective efficacy of 90.

NVX-CoV2373 is a recombinant protein candidate vaccine produced using Novavax’s recombinant nanoparticle technology.

Image source: Novavax official website

PREVENT-19, conducted in the United States and Mexico, is a randomized, double-blind, placebo-controlled, pivotal phase 3 clinical trial.

77 symptomatic COVID-19 cases were observed in the trial, of which 63 were observed in the placebo group and 14 cases were observed in the NVX-CoV2373 group.

The effectiveness of NVX-CoV2373 in the "high-risk" population was 91.

▲NVX-CoV2373 has an overall protection effect of 90.

▲Distribution of new coronavirus mutant strains discovered through genome sequencing (picture source: reference [1])

Preliminary safety data of PREVENT-19 show that the vaccine is generally well tolerated, with a small number of serious adverse events, and a balance between the vaccine group and the placebo group

▲NVX-CoV2373 safety data (picture source: reference [1])

Note: The original text has been deleted

Reference materials:

[1] PREVENT-19 Phase 3 TrialData Factsheet.

▽ attention [drug Mingkang Germany ] micro-channel public number